T

here was an excitement evident at this week’s meeting of stem cell scientists in Boston, with speakers highlighting how the years of toil in labs were approaching payoffs for patients, as more cell therapies have moved into clinical trials and researchers have gained a greater understanding of how to maximize their promise.

“This is our century,” Sally Temple, the president of the International Society for Stem Cell Research, said as thousands of experts milled about.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy